Covid-19 tumult prompts rethink of buy-side risk management

Buy-side risk survey: investment firms making changes to their risk reports, stress tests and concentration limits


This is the eleventh in a series of articles connected to our buy-side risk survey. Click here to read the rest of the series.

Evolution rather than revolution. Now that markets have, at least for now, bounced back from March’s lows, this is how buy-side firms describe the impact of the Covid-19 crisis on risk management. But whether profound or otherwise, changes in approaches will be multiple and wide-spread.

For Sudi Mariappa, global head of portfolio risk management at Pimco, the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here:

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: